Explore
Search ClinicalTrials.gov
Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.
Results for “Novartis”
Sponsor: Novartis Pharmaceuticals
Geographic Atrophy Secondary to Age-related Macular Degeneration
United States, Australia, Bulgaria, Canada, Czechia +10 more
- CINC424A2X01B Rollover ProtocolActive Not Recruiting
Sponsor: Novartis Pharmaceuticals
Primary Myelofibrosis · Polycythemia Vera · Graft Versus Host Disease · Acute Myeloid Leukemia
Australia, Belgium, Bulgaria, Canada, Chile +20 more
- A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)Active Not Recruiting
Sponsor: Novartis Pharmaceuticals
Hidradenitis Suppurativa
United States, Argentina, Australia, Bulgaria, Canada +15 more
- A Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Moderate to Severe Cutaneous Lichen PlanusNot Yet Recruiting
Sponsor: Novartis Pharmaceuticals
Cutaneous Lichen Planus
- Iptacopan in Patients With ANCA Associated VasculitisActive Not Recruiting
Sponsor: Novartis Pharmaceuticals
Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis
United States, Argentina, Australia, Austria, Belgium +10 more
Sponsor: Brown University
Sickle Cell Anemia in Children · Sickle Cell Disease
Angola
- Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CPRecruiting
Sponsor: Novartis Pharmaceuticals
Chronic Myelogenous Leukemia · Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive
United States, Australia, Brazil, Canada, China +8 more
Sponsor: Novartis Pharmaceuticals
Breast Cancer
United States, Australia, Canada, China, France +6 more
- A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistaminesActive Not Recruiting
Sponsor: Novartis Pharmaceuticals
Chronic Inducible Urticaria
United States, Argentina, Australia, Brazil, Canada +23 more
- Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior TreatmentActive Not Recruiting
Sponsor: RTOG Foundation, Inc.
Intracranial Meningioma
United States
- A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic SclerosisRecruiting
Sponsor: Novartis Pharmaceuticals
Diffuse Cutaneous Systemic Sclerosis
United States, Argentina, Austria, Belgium, Brazil +20 more
Sponsor: Novartis Pharmaceuticals
Still´s Disease
United States, Canada, France, Germany, Italy +3 more
Sponsor: Novartis Pharmaceuticals
Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)
United States, France, Germany, Poland, Spain
- A Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab EmiratesNot Yet Recruiting
Sponsor: Novartis Pharmaceuticals
Hypertension
Sponsor: Novartis Pharmaceuticals
Cryptosporidiosis
United States
Sponsor: Novartis Pharmaceuticals
Non-segmental Vitiligo
United States, Argentina, Australia, Canada, China +7 more
- A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MSNot Yet Recruiting
Sponsor: Moein Amin
Multiple Sclerosis (MS) - Relapsing-remitting · Multiple Sclerosis (MS) Secondary Progressive · Multiple Sclerosis (MS) Primary Progressive
United States
- Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive PatientsActive Not Recruiting
Sponsor: Novartis Pharmaceuticals
B-Cell Acute Lymphoblastic Leukemia
United States, Belgium, Canada, Denmark, France +6 more
Sponsor: Novartis Pharmaceuticals
Asthma
Argentina, Austria, Brazil, Bulgaria, Colombia +12 more
Sponsor: Novartis Pharmaceuticals
Asthma
South Africa
Sponsor: Novartis Pharmaceuticals
Scleroderma, Diffuse
United States, Argentina, Australia, Austria, Belgium +17 more
- A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and AtezolizumabActive Not Recruiting
Sponsor: Novartis Pharmaceuticals
Extensive Stage Small Cell Lung Cancer
United States, Austria, Canada, China, Czechia +7 more
Sponsor: Novartis Pharmaceuticals
Indication of the Parent Protocol
Bulgaria, Canada, Czechia, France, Poland +3 more
Sponsor: Novartis Pharmaceuticals
Sickle Cell Disease
United States, Brazil, Colombia, Kenya, Uganda
Sponsor: Novartis Pharmaceuticals
Dermatitis, Atopic
Japan